Proposals to facilitate compulsory licensing in Brazil extend beyond the COVID-19 crisis to other public health emergencies. While industry says the proposals are unnecessary and would damage investment in the sector, public health advocates argue they come as a result of pharma’s failure to engage with voluntary mechanisms to ensure demand for COVID-19 vaccines is met.
The most significant thing about the proposed provisions is that they address technology transfer needs by compelling the IP holder...
